Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.64-0.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VERU
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment and progress interim and topline analyses for the Phase 2b PLATEAU trial evaluating enobosarm with semaglutide for quality weight loss in older obese patients.
Stated as a priority in 2 of last 2 quarters. Management reported full enrollment of 239 patients in the Phase 2b PLATEAU trial by 2026-Q2, up from active enrollment in 2026-Q1. Interim analysis is expected in Q1 2027 and final data in Q4 2027. The trajectory is delivering consistent progress toward clinical milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Reached full enrollment of the Phase 2b PLATEAU clinical trial and entered clinical supply agreement with Novo Nordisk.”
“Phase 2b PLATEAU clinical trial is actively enrolling and on track for interim analysis in Q1 2027.”
Secure and expand patent protection for enobosarm in combination with weight loss drugs, including a key US patent allowance extending protection to at least October 2044.
Newly stated in 2026-Q2. Management announced a USPTO notice of allowance for a key US patent for enobosarm combined with semaglutide, expected to provide patent protection until at least October 2044. This represents a recent milestone in expanding the intellectual property portfolio.
“Received USPTO notice of allowance for key US patent for enobosarm with semaglutide, protection until at least October 2044.”
Focus on reducing operating losses and net losses through expense management and operational improvements.
Stated as a priority in 2 of last 2 quarters. Operating loss improved from $8.1 million in 2025-Q2 to $7.2 million in 2026-Q2, and net loss improved from $7.9 million to $2.7 million over the same period. The trajectory shows delivering progress in reducing losses.
“Operating loss from continuing operations decreased to $7.2 million from $8.1 million; net loss decreased to $2.7 million from $7.9 million.”
“Operating loss decreased to $7.7 million from $7.5 million; net loss decreased to $5.3 million from $8.9 million.”
Manage capital through agreements such as clinical supply contracts and debt issuance to support clinical development and operations.
Stated in 2 of last 2 quarters. Management disclosed a clinical supply agreement with Novo Nordisk and a sales agreement for potential common stock issuance in 2026. These actions indicate active capital allocation to support clinical programs and operations, consistent with stated priorities.
“Entered into a sales agreement to issue and sell common stock through sales agents.”
“Entered clinical supply agreement with Novo Nordisk for Phase 2b PLATEAU trial.”
Entered into a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU clinical study.
Over the trailing year it converted 1.08x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.